Community practices are crucial for helping to increase diversity in clinical trials, said James Hamrick, MD, MPH, Kaiser Permanente and Flatiron Health.
Community practices are crucial for helping to increase diversity in clinical trials, said James Hamrick, MD, MPH, Kaiser Permanente and Flatiron Health.
Transcript
How can we diversify the patient population in clinical trials?
Diversity within clinical trials has been an issue for a long time and it continues to be. And, I think one thing that you can do with a huge community network, so one thing that community oncology can do is they can provider that denominator, so to speak, of patients that really do reflect the US population right now.
So, if you have a network that stretches across the country that’s rural and urban, that goes from small 1 doctor practices to very large, sophisticated practices with dozens of oncologists, then you really are getting a good snapshot of what the US population looks like. And that’s crucial, because we know that there are groups of patients that are traditionally underrepresented. Whether it be on racial lines or gender lines or age lines or socioeconomic lines, we know that the traditional clinical trials model that we’ve been operating under does not truly represent the real world. And oncologists know this well. We’ve always know it. And, so, you’re always trying to extrapolate. So, I think, having a network that touches all of the different places that cancer patients in our country get care is one huge step in terms of increasing diversity.
In addition, there is a shift in the mindset. So, there have been very good reasons for some populations in the United States to not trust clinical research. You think of Tuskegee [syphilis experiment] and it’s very reasonable to be skeptical of the motives of clinical research. I think we’re moving to an era where more and more people understand that we have a lot more safeguards for patients and research subjects now—that’s hugely important.
And, actually now people understand that, “Hey, the best cancer care is care that has access for cutting-edge trials.” So, I think that’s a transformative moment, and that’s a message that we need to continue to send as the oncology community is that: “You should be asking your doctor and your practice about access to trials.” Because that really is a hallmark of excellence in care.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More